Sacituzumab tirumotecan

Sacituzumab tirumotecan (sac-TMT, MK-2870) is an antibody-drug conjugate that pairs an antibody targeting TROP2, a surface protein common on solid tumors, with a topoisomerase I inhibitor payload that jams the machinery cancer cells need to copy their DNA [1]. The specific node here references NCT06788912, a Phase 2 neoadjuvant combination with pembrolizumab in resectable non-small cell lung cancer (NSCLC) under Merck's KEYMAKER-U01 umbrella [2]. But that trial is one small piece of a much larger Merck program: sac-TMT is one of Merck's headline post-Keytruda assets, with active Phase 3 trials in breast cancer, endometrial cancer, and squamous NSCLC, and a practice-changing Phase 3 readout in EGFR-TKI-resistant NSCLC published in NEJM in early 2026 [3]. Originally developed by China-based Kelun-Biotech as SKB264, with Merck holding global ex-China rights through 2022 licensing deals. With Keytruda facing loss of exclusivity around 2028 and Merck pulling in roughly $65B in 2025 revenue, sac-TMT is the kind of bet that has to land [5].

Sac-TMT is a novel compound, not yet approved by FDA, though that should change within the next 12-18 months. (It has been approved in China by NMPA for both TNBC and EGFR-mutated NSCLC [10].) The trial referenced in this node is Phase 2, but the program's center of gravity has shifted to Phase 3. NEJM published Phase 3 results showing sac-TMT extended progression-free survival in EGFR-mutated NSCLC patients who had progressed on TKIs like osimertinib - the first TROP2-ADC to show Phase 3 benefit in EGFR-TKI-resistant, EGFR-mutated NSCLC [3]. Merck has signaled regulatory filings will follow. Active Phase 3 trials include TroFuse-033 in mismatch-repair-proficient endometrial cancer (n=1,123) [6], TroFuse-032 / MK-2870-032 in early-stage TNBC and HR-low+/HER2− breast cancer (n=2,400) [7], and MK-2870-023 in metastatic squamous NSCLC (n=851) [8]. The Phase 2 KEYMAKER substudy in resectable NSCLC that anchors this node is a smaller bet, n=60 single-arm, exploring whether adding the ADC to pembrolizumab can drive deeper pathological responses before surgery [2]. No FDA breakthrough designation has been publicly disclosed for sac-TMT as of writing, though one would not be surprising given the EGFR-TKI-resistant data.

TROP2 (gene name TACSTD2) is a surface protein found at high levels on many solid tumors including most NSCLC, breast, and bladder cancers, but at lower levels on most normal tissues. That differential expression is what makes it useful for targeting: dose the antibody, it binds tumor cells preferentially. Sac-TMT's antibody finds TROP2, the whole complex gets pulled inside the cell, and a pH-sensitive cleavable linker releases the topoisomerase I inhibitor payload in the lysosome. Topoisomerase I is the enzyme cells use to relieve tension in DNA strands during replication. Block it and DNA replication snaps, the cell tries to fix it, fails, and dies [1]. The payload here is KL610023, a belotecan-derivative camptothecin distinct from SN-38 (the irinotecan-derivative payload used in Trodelvy) and from DXd/exatecan-derivative (the payload used in Datroway and trastuzumab deruxtecan) [10]. Sac-TMT carries a drug-to-antibody ratio of ~7.4, on the high end of the class (Datroway DAR ~4; Trodelvy DAR ~7.6) [10]. The payload is also membrane-permeable enough to leak into neighboring cells, killing TROP2-negative cells in the tumor too (the so-called bystander effect, which matters when TROP2 expression is patchy). The mechanism is well-validated: sacituzumab govitecan (Trodelvy, Gilead) is an approved TROP2-ADC in TNBC and urothelial cancer; datopotamab deruxtecan (Datroway, AstraZeneca/Daiichi Sankyo) is an approved TROP2-ADC in HR+/HER2− breast cancer and now EGFR-mutated NSCLC [11]. The open question on sac-TMT is execution rather than target choice: does its specific antibody, novel payload, linker chemistry, and high DAR translate into better efficacy or tolerability than the entrenched competition [9]?

NCT06788912 is substudy 01E of MK-3475-01E (KEYMAKER-U01), a Merck umbrella platform that tests pembrolizumab-plus-investigational-agent combinations in neoadjuvant resectable NSCLC [2]. Sac-TMT is one of several investigational agents being run through the platform. Target enrollment is 60 patients, Phase 2, single-arm, recruiting. The primary endpoint is pathological complete response (pCR), meaning the fraction of patients whose surgically removed tumor and lymph nodes show no residual cancer after neoadjuvant treatment. pCR is an FDA-accepted accelerated-approval endpoint in some settings (early-stage breast cancer) but in NSCLC its role is less settled. Merck's own perioperative pembrolizumab regimen (KEYNOTE-671, approved as Keytruda plus chemo neoadjuvant) set a benchmark around 18-20% pCR - but KEYNOTE-671 included chemotherapy in the neoadjuvant arm, while NCT06788912 pairs sac-TMT with pembrolizumab and no platinum doublet. That asymmetry is important: a chemo-free regimen achieving 25-30% pCR would be a meaningfully different signal than matching a chemo-containing regimen, since the read on toxicity and quality of life is different too. The umbrella design is efficient (shared control infrastructure, fast triage of combinations), but small single-arm cohorts in heterogeneous NSCLC populations can mislead, since non-randomized pCR data is notoriously noisy. The bigger reads on sac-TMT will come from the randomized Phase 3 trials in other indications, not this substudy. As of the most recent update, the trial is recruiting and no readout date has been disclosed.

The model puts this drug's chance of eventual approval at 7%. It starts from the historical approval rate for Phase 2 drugs in this area - about 13% - then adjusts up or down based on ten facts about the trial and sponsor. The biggest boosts come from the trial's blinding approach, more secondary endpoints than usual, and the sponsor's strong approval track record; the biggest drag is weak earlier-phase results. The remaining factors fall close to average, so they don't shift the estimate much from that starting point.

Safety is the first concern. ADC payloads in this class carry known toxicities: sacituzumab govitecan has black-box warnings for severe neutropenia and diarrhea. The NEJM Phase 3 data on sac-TMT in EGFR-TKI-resistant NSCLC showed a manageable but non-trivial safety profile, including stomatitis (mouth sores), neutropenia, and anemia [3]. Adding sac-TMT to pembrolizumab in a neoadjuvant setting compounds the risk: patients are about to undergo curative-intent surgery, so any treatment-related delays or complications hit hard. Interstitial lung disease (ILD), the recurring problem of topoisomerase-I-ADC programs (datopotamab deruxtecan's Phase 3 data flagged ILD as a clinical concern), is something to watch in a lung cancer population specifically. Efficacy risk: pCR in a 60-patient single-arm Phase 2 is a soft endpoint. A 25-30% pCR rate could look strong or weak depending on the comparator framing, and Merck's own perioperative Keytruda regimen sets the benchmark to beat. Competitive risk: datopotamab deruxtecan (Datroway) received FDA accelerated approval on June 23, 2025 for locally advanced or metastatic EGFR-mutated NSCLC in patients who progressed on prior EGFR-directed therapy and platinum chemotherapy [11] - meaning Daiichi/AstraZeneca already hold the exact lung indication sac-TMT's NEJM data targets. Sac-TMT will be entering an FDA filing process where the first-mover has a label, sales force, and 12+ months of post-marketing experience. Commercial risk: ADCs run roughly $150-200K per year of treatment, and payer pushback on combination ADC plus anti-PD-1 regimens is becoming standard, particularly when incremental benefit over existing care is modest.

Worth watching, but not because of this specific substudy. The KEYMAKER 01E neoadjuvant cohort is too small and too early to move the needle on its own. What matters is the broader sac-TMT program. Merck has built this into one of the two or three largest post-Keytruda revenue plays. Keytruda generated $31.7B in 2025 [5], and Merck expects U.S. Keytruda revenue to decline materially after entering government price setting in 2029 [5] - Merck needs replacements that can absorb that revenue base. Sac-TMT, MK-1084 (KRAS G12C), and the next-gen IO assets are the leading candidates. Catalysts to watch: (1) Phase 3 breast (TroFuse-032 / MK-2870-032, n=2,400) and endometrial (TroFuse-033, n=1,123) readouts, both with high commercial use [6,7]; (2) FDA submission and approval timing for the NEJM-published EGFR-TKI-resistant NSCLC indication, which would be the first sac-TMT approval in the U.S. [3] - but Datroway already holds this indication as of June 2025 [11], so sac-TMT will need to differentiate on response rate, duration, or safety; (3) head-to-head positioning versus AstraZeneca/Daiichi's datopotamab deruxtecan, the other contender for the lung TROP2 throne. Specific Phase 3 readout windows for TroFuse-032 and TroFuse-033 have not been publicly disclosed by Merck; both completed enrollment infrastructure in 2025 and are most likely candidates for late-2026 or 2027 ASCO/ESMO updates, but treat that timing as inference rather than guidance. Check Merck's quarterly earnings calls, where sac-TMT is now a named asset Merck calls out in pipeline commentary [5]. For NCT06788912 specifically, the read is whether Merck graduates it to a randomized Phase 3 perioperative NSCLC program. If yes, signal. If quietly retired, the umbrella did its job and the bet moved elsewhere.